Literature DB >> 34080108

Who Will Be Responsible for the Dialysis Bill? A Case Report and Narrative Review of Insulin Affordability 100 Years After the Discovery of Insulin.

Alheli Arce Gastelum1, Sima Maraqa2, Walter Ariel Marquez Lavenant3, Ammara Khan2, Robert S McMahon4, Azka Latif2, Theresa A Townley5.   

Abstract

A 46-year-old woman was type 1 diabetes diagnosed at the age of 9 who had previously been on an insulin pump. Other co-morbidities included CKD IV, HTN, and hypothyroidism. She presented with hyperglycemia of 400 mg/dl and fluid retention. Her GFR had decreased to 13. Her physical exam was notable for respiratory distress and anasarca. She failed to respond to aggressive IV diuresis and urgent hemodialysis was initiated. The patient had been lost to outpatient follow-up for a year. She had been co-managed by an endocrinologist and a primary care physician but had stopped going to her endocrinologist over a year ago due to inability to afford the co-pays. She subsequently lost her insurance and had to pay out of pocket for her insulin; at this point, she decided to stop seeing her PCP and began to ration her insulin. Due to social stigma, she did not mention her financial issues to her healthcare providers. After identifying these challenges, we decided to start her on a more affordable regimen of NPH insulin. Through social work assistance, we were able to obtain a charity hemodialysis chair and discharge her home. She applied to Medicaid. Healthcare expenditure with regard to diabetes rose to $327 billion from $245 billion in 2012. The price of insulin has continued to increase even after the drug's patent has expired due to the combination of FDA requirements, a monopoly in the insulin market, and the lack of federal price controls and Pharmacy Benefits Managers. The high out of pocket costs for insulin has led to many instances of insulin rationing among both uninsured and insured. This led to death in some cases as well as poorly controlled diabetes with increased complications and mortality as in our case. We present a case report and narrative review on insulin affordability.

Entities:  

Keywords:  chronic kidney disease; dialysis; end-stage renal disease; healthcare disparities; insulin; insulin cost; narrative review; type one diabetes; type two diabetes

Year:  2021        PMID: 34080108     DOI: 10.1007/s11606-021-06886-3

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  8 in total

Review 1.  Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.

Authors:  Hsin-Chieh Yeh; Todd T Brown; Nisa Maruthur; Padmini Ranasinghe; Zackary Berger; Yong D Suh; Lisa M Wilson; Elisabeth B Haberl; Jessica Brick; Eric B Bass; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

Review 2.  Insulin Access and Affordability Working Group: Conclusions and Recommendations.

Authors:  William T Cefalu; Daniel E Dawes; Gina Gavlak; Dana Goldman; William H Herman; Karen Van Nuys; Alvin C Powers; Simeon I Taylor; Alan L Yatvin
Journal:  Diabetes Care       Date:  2018-05-08       Impact factor: 19.112

3.  Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective.

Authors:  David Beran; Irl B Hirsch; John S Yudkin
Journal:  Diabetes Care       Date:  2018-06       Impact factor: 19.112

4.  Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014.

Authors:  Jing Luo; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2015-10       Impact factor: 21.873

5.  Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.

Authors:  Xinyang Hua; Natalie Carvalho; Michelle Tew; Elbert S Huang; William H Herman; Philip Clarke
Journal:  JAMA       Date:  2016-04-05       Impact factor: 56.272

6.  The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes.

Authors:  Timothy M Dall; Wenya Yang; Karin Gillespie; Michelle Mocarski; Erin Byrne; Inna Cintina; Kaleigh Beronja; April P Semilla; William Iacobucci; Paul F Hogan
Journal:  Diabetes Care       Date:  2019-04-02       Impact factor: 19.112

7.  Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?

Authors:  Kelly George; Gillian Woollett
Journal:  BioDrugs       Date:  2019-10       Impact factor: 5.807

8.  Role of self-care in management of diabetes mellitus.

Authors:  Saurabh Rambiharilal Shrivastava; Prateek Saurabh Shrivastava; Jegadeesh Ramasamy
Journal:  J Diabetes Metab Disord       Date:  2013-03-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.